PureTech Health plc PTCHF
Set alert
1.56 USD 0.00 0.00%
At close · Oct 30
1.56 Day range 1.56
1.45 52-week range 1.92
- YTD
- -8.77%
- 1 year
- -7.14%
- Open
- 1.56
- Prev close
- 1.56
- Mkt cap
- 382.48M
- Vol
- 8.85K
- Avg vol
- 1.06K
- EPS
- 0.00
- P/E
- 0.00
More statistics
- Low
- 1.56
- High
- 1.56
6M chart
Signals (21)
| Name | Date | Ago |
|---|---|---|
| SMA: Bearish | Oct 29, 2026 | 3 days ago |
| SMA: Bullish | Oct 22, 2026 | 1 week ago |
| MACD: Buy Signal | Oct 22, 2026 | 1 week ago |
| SMA: Bearish | Sep 23, 2026 | 1 month ago |
| MACD: Sell Signal | Sep 23, 2026 | 1 month ago |
| RSI: Oversold | Sep 23, 2026 | 1 month ago |
| SMA: Bullish | Sep 8, 2026 | 1 month ago |
| RSI: Overbought | Sep 8, 2026 | 1 month ago |
| MACD: Buy Signal | Aug 5, 2026 | 2 months ago |
| MACD: Sell Signal | Jul 27, 2026 | 3 months ago |
| MACD: Buy Signal | Jul 21, 2026 | 3 months ago |
| RSI: Oversold | Jul 6, 2026 | 3 months ago |
| SMA: Bearish | Jun 11, 2026 | 4 months ago |
| SMA: Bearish | Jun 11, 2026 | 4 months ago |
| MACD: Sell Signal | Jun 11, 2026 | 4 months ago |
| SMA: Bullish | May 26, 2026 | 5 months ago |
| SMA: Bullish | May 26, 2026 | 5 months ago |
| MACD: Buy Signal | May 26, 2026 | 5 months ago |
| SMA: Bearish | May 21, 2026 | 5 months ago |
| MACD: Sell Signal | May 7, 2026 | 5 months ago |
| RSI: Overbought | May 1, 2026 | 6 months ago |
Financials — quick view
PTCHF Revenue — quarterly 5.73M
PTCHF Net income — quarterly 73.00K
PTCHF EPS — quarterly 0.02
News
- PureTech Founded Entity Seaport Therapeutics Presents Additional Pharmacokinetic Data from Phase 1 Clinical Trial of GlyphAgo™ at the 39th European College of Neuropsychopharmacology (ECNP) Congress
- PureTech Health gets Panmure Liberum ‘buy' on value and cash returns
- PureTech Health: Results of Annual General Meeting
- PureTech Health shares boosted as investee Seaport Therapeutics prices Nasdaq IPO
- PureTech Health shares boosted as investee Seaport Therapeutics prices Nasdaq IPO
- PureTech Health plc (PRTC) Q4 2025 Earnings Call Transcript
- Short Interest in PureTech Health plc (OTCMKTS:PTCHF) Expands By 69.4%
- Cavendish sees Poolbeg’s POLB 001 gaining strategic importance as CRS research expands
- Greengage plans AQSE float with bold Bitcoin-backed lending strategy
- Puretech gains after FDA meeting post-Phase II trial
Your note
Sign in to keep a note on PTCHF — it syncs with the Stock Master app.